Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hemoblock is a topical hemostatic agent composed of a silver salt of polyacrylic acid (silver polyacrylate). It is primarily indicated for the management of capillary and parenchymal hemorrhages during surgical interventions, trauma, and dental procedures. The drug's mechanism of action involves the rapid formation of a stable protein-polyacrylate complex upon contact with blood proteins, particularly albumin. This process results in the creation of a mechanical barrier or clot that seals damaged vessels without relying on the patient's endogenous coagulation factors, making it effective even in the presence of coagulopathies or anticoagulant therapy. Furthermore, the presence of silver ions imparts broad-spectrum antimicrobial properties to the solution, which helps prevent secondary wound infections. Hemoblock is typically applied topically as a solution or via impregnated dressings and is characterized by its minimal tissue reaction and lack of systemic absorption.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on silver polyacrylate.